<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> is an autoinflammatory syndrome characterized by <z:hpo ids='HP_0003623'>neonatal onset</z:hpo> of <z:e sem="disease" ids="C0042109" disease_type="Disease or Syndrome" abbrv="">urticarial rash</z:e>, central <z:mp ids='MP_0008912'>nervous</z:mp> system lesions and <z:hpo ids='HP_0003040'>arthropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Laboratory findings show leucocytosis, <z:hpo ids='HP_0001903'>anemia</z:hpo>, elevation of CRP levels and acceleration of ESR </plain></SENT>
<SENT sid="2" pm="."><plain>The syndrome is associated with CIAS1 gene and its encoding protein cryopyrin </plain></SENT>
<SENT sid="3" pm="."><plain>The CIAS1 gene is expressed in monocytes, polymorphonuclear cells and chondrocytes </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations of cyropyrin lead to the persistent production of IL-1beta and activation of NF-kappaB, followed by excessive inflammtory reactions </plain></SENT>
<SENT sid="5" pm="."><plain>In spite of aggressive therapies, the <z:mp ids='MP_0001845'>inflammation</z:mp> persists and the lesions are progressive </plain></SENT>
<SENT sid="6" pm="."><plain>Recently, there have been reports of clinical improvement using human recombinant IL-1 receptor antagonsist anakinra in the patients with <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> and its related diseases, Muckele-Wells syndrome and <z:e sem="disease" ids="C1610600" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">familial cold-autoinflammatory syndrome</z:e>, suggesting that IL-1beta plays an important role in the pathogensis of the <z:mp ids='MP_0001845'>inflammation</z:mp> associated with the CIAS1 gene mutations </plain></SENT>
<SENT sid="7" pm="."><plain>No serious adverse reaction of anakinra has not been reported </plain></SENT>
<SENT sid="8" pm="."><plain>Following the diagnosis of <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e>, anakinra therapy should be started as the first line of therapy before irreversible disabilities develop </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with anakinra has just begun, therefore, it is necessary to carry out further investigations concerning the adverse effects of anakinra and long-term prognosis for <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> treated with anakinra </plain></SENT>
</text></document>